CD131抗体;CD131 Antibody—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Western blot analysis using CD131 mouse mAb against NIH/3T3 (1), Hela (2), C6 (3), HL-60 (4), Jurkat (5), MCF-7 (6), and PC-12 (7) cell lysate.    

  
  

•  

   

     Flow cytometric analysis of Hela cells using CD131 mouse mAb (green) and negative control (red).    

  
  

CD131. also known as the β common chain (βc), is a shared subunit of receptors for interleukin-3 (IL-3), interleukin-5 (IL-5), and granulocyte-macrophage colony-stimulating factor (GM-CSF). These cytokines regulate hematopoiesis, immune cell activation, and inflammation. CD131 antibodies target this critical receptor component, which is expressed on myeloid cells, eosinophils, and certain leukemia cells. Research on CD131 antibodies stems from their potential to modulate dysregulated immune responses in diseases like asthma, autoimmune disorders, and myeloid leukemias, where aberrant cytokine signaling drives pathology.

The development of CD131 antibodies has been driven by the need to block pathogenic signaling cascades. For example, in eosinophil-mediated inflammation (e.g., severe asthma), antibodies inhibiting IL-5/CD131 interaction reduce eosinophil activation. In oncology, CD131 is explored as a therapeutic target due to its overexpression in acute myeloid leukemia (AML) and role in leukemia stem cell survival. Antibodies against CD131 may disrupt pro-survival signals or enable antibody-dependent cellular cytotoxicity (ADCC).

Current challenges include optimizing specificity to avoid off-target effects on healthy hematopoietic cells and understanding receptor dimerization dynamics. Nonetheless, CD131 antibodies represent a promising tool for precision immunotherapy, with ongoing studies evaluating their efficacy alone or combined with other agents to enhance therapeutic outcomes.